Skip to content
OpenCapital
Get started

Sutro Biopharma STRO Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

SPS Commerce logo
SPS CommerceSPSC
$4.87M+54.2%
AvePoint, Inc. logo
AvePoint, Inc.AVPT
$4.39M+4.3%
Q2 Holdings logo
Q2 HoldingsQTWO
$45.49M+26.0%
AMN Healthcare logo
AMN HealthcareAMN
-$4.41M-312%
Rackspace Technology, Inc. logo
Rackspace Technology, Inc.RXT
$35.6M+483%
Calix logo
CalixCALX
$675K-80.6%

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%—
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's increase (decrease) in contract liabilities and current deferred income?
Sutro Biopharma (STRO) reported increase (decrease) in contract liabilities and current deferred income of -$1.96M in Q1 2026.
How has Sutro Biopharma's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Sutro Biopharma's increase (decrease) in contract liabilities and current deferred income increased by 59.0% year-over-year, from -$4.78M to -$1.96M.
What is the long-term trend for Sutro Biopharma's increase (decrease) in contract liabilities and current deferred income?
Over 2 years (2021 to 2025), Sutro Biopharma's increase (decrease) in contract liabilities and current deferred income has grown at a 114.1% compound annual growth rate (CAGR), from -$15.21M to -$69.73M.